Celltrion
068270.KS
#747
Rank
โ‚ฌ27.56 B
Marketcap
125,99ย โ‚ฌ
Share price
1.40%
Change (1 day)
11.79%
Change (1 year)
Celltrion is a Korean pharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion.

P/E ratio for Celltrion (068270.KS)

P/E ratio as of February 2026 (TTM): 78.5

According to Celltrion 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 78.5104. At the end of 2024 the company had a P/E ratio of 91.6.

P/E ratio history for Celltrion from 2008 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202491.649.24%
202361.343.97%
202242.6-9.69%
202147.2-49.48%
202093.417.79%
201979.3-27.7%
201811045.28%
201775.5-7.14%
201681.326.52%
201564.377.15%
201436.3-3.29%
201337.5152.7%
201214.8-40.11%
201124.8-26.42%
201033.731.03%
200925.7-60.87%
200865.7785.83%
20077.41

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.